With Friday's announcement that the FDA has approved Vyzulta, Valeant and Nicox's novel new glaucoma therapy, the eyecare world gets its first new treatment for glaucoma since prostaglandins entered the market in 2001! Numerous efficacy studies point towards Vyzulta being the most effective intraocular pressure (IOP) lowering medication to date. Vyzulta combines tried and true prostaglandin analogue latanprostene with nitric oxide to target...